Theranica's Nerivio, a smartphone-controlled therapeutic wearable for migraines, gained commercial coverage with Highmark Inc., covering 7 million individuals across four states. Results from a study of 384 Highmark migraine sufferers showed 75% experienced pain relief within two hours, with 37.3% reporting pain freedom and 69% indicating significant relief. Theranica's CEO, Alon Ironi, hailed this as a breakthrough for non-pharmacological migraine treatment, stressing the need for wider accessibility. The device, FDA-approved since 2020, utilizes remote electrical neuromodulation (REN) to activate nerve fibers in the arm, triggering pain management mechanisms in the brain without medication. Each 45-minute treatment, self-administered via a smartphone app, costs $599, with the first device available for $10 under the Nerivio Direct Savings Program. Additionally, it is covered by the United States Veterans Administration (VA) system health insurance.